David Jakob Lemus CPA serves as Independent Director of the Company. and development of T-Cell-Receptor based immunotherapies. Prior to that time, at Sigma Tau Pharmaceuticals, Inc., he served as Chief Executive Officer from January 2013 to July 2015, as Chief Operating Officer from March 2012 to December 2012, and as V.P. Finance from July 2011 to February 2012. Previous to this, Mr. Lemus served as Chief Financial Officer and Executive V.P. of MorphoSys AG from January 1998 to May 2011. Prior to his role at MorphoSys AG, he held various positions, including Operations Manager and Controller (Pharma International Division) and Global IT Project Manager (Pharma Division) at Hoffman La Roche, Group Treasurer of Lindt & Spruengli AG and Treasury Consultant for Electrolux AB.
As the Independent Director of Sorrento Therapeutics Inc, the total compensation of David Lemus at Sorrento Therapeutics Inc is 291,400$. There are 7 executives at Sorrento Therapeutics Inc getting paid more, with Jaisim Shah having the highest compensation of 10,971,100$.
David Lemus is 57, he's been the Independent Director of Sorrento Therapeutics Inc since 2017. There are 4 older and 6 younger executives at Sorrento Therapeutics Inc. The oldest executive at Sorrento Therapeutics Inc is Dr. Michael A. Royal, 67, who is the SVP & Chief Medical Officer.
David's mailing address filed with the SEC is C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO, CA, 92121.
Over the last 15 years, insiders at Sorrento Therapeutics Inc have traded over 17,198,839$ worth of Sorrento Therapeutics Inc stock and bought 10,353,437 units worth 10,703,222$ . The most active insiders traders include Jane Ph D Hsiao、Edgar Lee、Patrick Chan Soon Shiong Fa.... On average, Sorrento Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of 2,947$. The most recent stock trade was executed by Henry Ji on 7 September 2022, trading 88,888 units of SRNE stock currently worth 179,554$.
sorrento therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical car-t therapies targeting solid tumors.
Sorrento Therapeutics Inc executives and other stock owners filed with the SEC include: